{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:21:19Z","timestamp":1758874879680},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:00:00Z","timestamp":1535328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s13318-018-0504-8","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T08:49:59Z","timestamp":1535359799000},"page":"229-236","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC\u2013MS\/MS and Its Application to A Pharmacokinetic Interaction Study"],"prefix":"10.1007","volume":"44","author":[{"given":"Shu","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Bin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia-Yan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,27]]},"reference":[{"issue":"1","key":"504_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrd3185","volume":"10","author":"E Perzborn","year":"2011","unstructured":"Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61\u201375.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"504_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","volume":"91","author":"BI Eriksson","year":"2009","unstructured":"Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br Vol. 2009;91(5):636\u201344.","journal-title":"J Bone Joint Surg Br Vol"},{"issue":"26","key":"504_CR3","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765\u201375.","journal-title":"N Engl J Med"},{"issue":"9632","key":"504_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31\u20139.","journal-title":"Lancet"},{"issue":"26","key":"504_CR5","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776\u201386.","journal-title":"N Engl J Med"},{"issue":"8","key":"504_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/jphp.12387","volume":"67","author":"S Antoniou","year":"2015","unstructured":"Antoniou S. Rivaroxaban for the treatment and prevention of thromboembolic disease. J Pharm Pharmacol. 2015;67(8):1119\u201332.","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"504_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jacc.2017.12.045","volume":"71","author":"Y Daaboul","year":"2018","unstructured":"Daaboul Y, Korjian S, Plotnikov AN, Burton P, Braunwald E, Wiviott SD, et al. Rivaroxaban and post-stroke neurological outcomes in patients with acute coronary syndrome. J Am Coll Cardiol. 2018;71(9):1048\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fphar.2016.00494","volume":"7","author":"K Ing Lorenzini","year":"2016","unstructured":"Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol. 2016;7:494\u20138.","journal-title":"Front Pharmacol"},{"issue":"1","key":"504_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"504_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455\u201366.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"504_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jcph.352","volume":"54","author":"KT Moore","year":"2014","unstructured":"Moore KT, Vaidyanathan S, Natarajan J, Ariyawansa J, Haskell L, Turner KC. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol. 2014;54(12):1407\u201320.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"504_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10557-012-6420-2","volume":"26","author":"V Fontana","year":"2012","unstructured":"Fontana V, Silva PS, Izidoro-Toledo TC, Biagi C, Oliveira EB, Gerlach RF, et al. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. Cardiovasc Drugs Ther. 2012;26(6):511\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"504_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/rcm.1040","volume":"17","author":"J Lee","year":"2003","unstructured":"Lee J, Son J, Lee M, Lee KT, Kim DH. Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography\/tandem mass spectrometry. Rapid Commun Mass Spectrome RCM. 2003;17(11):1157\u201362.","journal-title":"Rapid Commun Mass Spectrome RCM"},{"issue":"2","key":"504_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11094-005-0094-z","volume":"39","author":"VV Pisarev","year":"2005","unstructured":"Pisarev VV, Moskaleva NE, Zverkov YB, Smirnova LB, Belolipetskaya VG, Sukhanov YV. HPLC\/MS Determination of Enalapril and Enalaprilat in the Blood Plasma. Pharm Chem J. 2005;39(2):104\u20137.","journal-title":"Pharm Chem J"},{"issue":"1","key":"504_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4155\/fsoa-2016-0071","volume":"3","author":"D Halder","year":"2017","unstructured":"Halder D, Dan S, Pal MM, Biswas E, Chatterjee N, Sarkar P, et al. LC-MS\/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects. Future Sci OA. 2017;3(1):165\u201384.","journal-title":"Future Sci OA"},{"issue":"1","key":"504_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jpba.2008.10.012","volume":"49","author":"S Lu","year":"2009","unstructured":"Lu S, Jiang K, Qin F, Lu X, Li F. Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J Pharm Biomed Anal. 2009;49(1):163\u20137.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"504_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","volume":"29","author":"SF Zhou","year":"2007","unstructured":"Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687\u2013710.","journal-title":"Ther Drug Monit"},{"issue":"1\u20132","key":"504_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/03602539709037591","volume":"29","author":"S Rendic","year":"1997","unstructured":"Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29(1\u20132):413\u2013580.","journal-title":"Drug Metab Rev"},{"issue":"4","key":"504_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2165\/00003088-199325040-00003","volume":"25","author":"RJ MacFadyen","year":"1993","unstructured":"MacFadyen RJ, Meredith PA, Elliott HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. Clin Pharmacokinet. 1993;25(4):274\u201382.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"504_CR20","first-page":"142","volume":"32","author":"T Edeki","year":"1994","unstructured":"Edeki T, Johnston A, Li KWE, Turner P. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. Int J Clin Pharmacol Ther. 1994;32(3):142\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"504_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1524-6175.2004.03609.x","volume":"6","author":"PK Whelton","year":"2004","unstructured":"Whelton PK. Hypertension curriculum review: epidemiology and the prevention of hypertension. J Clin Hypertens. 2004;6(11):636\u201342.","journal-title":"J Clin Hypertens"},{"issue":"2","key":"504_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00003088-200342020-00004","volume":"42","author":"MT Donato","year":"2003","unstructured":"Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet. 2003;42(2):153\u201378.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"504_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","volume":"35","author":"JH Lin","year":"1998","unstructured":"Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35(5):361\u201390.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"504_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11317220-000000000-00000","volume":"48","author":"A Hisaka","year":"2009","unstructured":"Hisaka A, Kusama M, Ohno Y, Sugiyama Y, Suzuki H. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet. 2009;48(10):653\u201366.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"504_CR25","first-page":"206","volume":"66","author":"Health UDo, Human services F, Drug Administration CfDE, Research CfVm","year":"2001","unstructured":"Health UDo, Human services F, Drug Administration CfDE, Research CfVm. Guidance for Industry, Bioanalytical Method Validation. Fed Regist. 2001;66(4):206\u20137.","journal-title":"Fed Regist"},{"issue":"3","key":"504_CR26","first-page":"397","volume":"69","author":"XH Huang","year":"2005","unstructured":"Huang XH, Li J. Drug and Statistics Software (DAS). Am J Pharm Educ. 2005;69(3):397\u20138.","journal-title":"Am J Pharm Educ"},{"issue":"3","key":"504_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jpba.2011.02.006","volume":"55","author":"MC Wenlock","year":"2011","unstructured":"Wenlock MC, Barton P, Austin RP. A kinetic method for the determination of plasma protein binding of compounds unstable in plasma: specific application to enalapril. J Pharm Biomed Anal. 2011;55(3):385\u201390.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"504_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003495-198631030-00002","volume":"31","author":"PA Todd","year":"1986","unstructured":"Todd PA, Heel RC. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986;31(3):198\u2013248.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"504_CR29","doi-asserted-by":"publisher","first-page":"215s","DOI":"10.1111\/j.1365-2125.1984.tb02601.x","volume":"18","author":"RO Davies","year":"1984","unstructured":"Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18(Suppl 2):215s\u201329s.","journal-title":"Br J Clin Pharmacol"},{"issue":"2a","key":"504_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0002-9343(84)80055-8","volume":"77","author":"RO Davies","year":"1984","unstructured":"Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncloa F. Enalapril worldwide experience. Am J Med. 1984;77(2a):23\u201335.","journal-title":"Am J Med"},{"issue":"3","key":"504_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","volume":"30","author":"E Perzborn","year":"2010","unstructured":"Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"504_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11239-017-1495-z","volume":"43","author":"B Steppich","year":"2017","unstructured":"Steppich B, Dobler F, Brendel LC, Hessling G, Braun SL, Steinsiek AL, et al. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43(4):490\u20137.","journal-title":"J Thromb Thrombolysis"},{"issue":"suppl 2","key":"504_CR33","first-page":"642","volume":"5","author":"E Perzborn","year":"2007","unstructured":"Perzborn E, Lange U. Rivaroxaban\u2014an oral, direct Factor Xa inhibitor\u2014inhibits tissue factor-mediated platelet aggregation. J Thromb Haemost. 2007;5(suppl 2):642.","journal-title":"J Thromb Haemost"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0504-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T18:03:12Z","timestamp":1567792992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,27]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0504-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,27]]},"assertion":[{"value":"27 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No source of funding was used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors has any potential conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All experiments were approved by the Wenzhou Medical University Committee, and all of the experiments were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}